AYTU BIOPHARMA, INC (AYTU): auditor change — Aytu BioPharma restates Q1 FY2023 financials; warrant misclassification adds $5.6M liabilities

AYTU BIOPHARMA, INC

Audit committee concludes Sep 30, 2022 financials should be restated due to warrant misclassification as equity instead of liabilities.
Restatement increases total liabilities by $5.6M, decreases equity by $3.4M, and reduces net loss by $2.2M.
Material weakness in internal control over financial reporting identified; company working to remediate.
Company expects to file 10-Q/A for Sep quarter and then 10-Q for Dec quarter as soon as practicable.
Going forward, warrants will be classified as liabilities, which may adversely affect results of operations.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

AYTU BIOPHARMA, INC reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

and, accordingly, that such previously issued financial statements should no longer be relied upon

View on SEC.gov

Browse all auditor changes →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-023779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.